| ［1］Sunderktter C, Nast A, Worm M, et al. Guidelines on dermatomyositis-excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology［J］. JDDG, 2016, 14(3): 321.
［2］Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial［J］. Lancet, 2016, 387(10019): 671-678.
［3］饶志华. 甲氨蝶呤联合糖皮质激素治疗PM及DM临床效果分析［J］. 中国现代医生, 2016, 54(31): 78-80.
［4］梁志强, 姜凤云, 赵蕾, 等. 环磷酰胺联合激素对炎性肌病相关肺间质病变患者呼吸功能的改善评价［J］. 山西医药杂志, 2016, 45(22): 2647-2649.
［5］Ueno KI, Shimojima Y, Kishida D, et al. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis［J］. Int J Rheum Dis, 2016, 19(12): 1322-1330.
［6］de Souza RC, Fhc DS, Miossi R, et al. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity ［J］. Clin Exp Rheumatol, 2017, 35(6): 1011-1013.
［7］黄梓峰, 杨少铮, 岳梦颖, 等. 来氟米特治疗PM/DM的临床疗效分析［J］. 风湿病与关节炎, 2017, 6(6): 36-37.
［8］Hayashi M, Kikuchi T. Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies ［J］. Clin Rheumatol, 2017, 36(1): 239-240.
［9］Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules［J］. Brit J Dermatol, 2017, 177(5): 1442-1446.
［10］Abdelhafidh NB, Toujeni S, Kefi A, et al. Dermatomyositis and Panniculitis: the function of immunoglobulins［J］. PAMJ, 2016, 23:262.
［11］Wan J, Imadojemu S, Werth VP. Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum［J］. Clin Dermatol, 2016, 34(3):344.
［12］Spencer CH, Rousterstevens K, Gewanter H, et al. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America［J］. Pediatr Rheumatol, 2017, 15(1): 50.
［13］Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial ［J］. Trials, 2017, 18(1): 275.
［14］Ogawa Y, Dai K, Shimojima Y, et al. Effective Administration of rituximab in anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease and refractory cutaneous involvement: a case report and literature review［J］. Case Rep Rheumatol, 2017, 2017: 5386797.
［15］Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab［J］. Rheumatology, 2016, 56(2): 247.
［16］Schiffenbauer A, Garg M, Castro C, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis ［J］. Semin Arthritis Rheum, 2018, 47(6): 858-864.
［17］Tjrnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial ［J］. Ann Rheum Dis, 2018, 77(1): 55-62.
［18］Arabshahi B, Silverman RA, Jones OY. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis ［J］. J Pediatr, 2012, 160: 520-522.
［19］Cozzi F, Marson P, Pigatto E, et al. Plasma-exchange as a "rescue therapy" for dermato/polymyositis in acute phase. Experience in three young patients ［J］. Transf Apheresis Sci, 2015, 53(3): 368-372.
［20］Kaieda S,Yoshida N,Yamashita F, et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis［J］. Modern Rheumatol, 2015, 25(6): 962-966.
|
